BRPI0923652A2 - diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 - Google Patents

diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Info

Publication number
BRPI0923652A2
BRPI0923652A2 BRPI0923652A BRPI0923652A BRPI0923652A2 BR PI0923652 A2 BRPI0923652 A2 BR PI0923652A2 BR PI0923652 A BRPI0923652 A BR PI0923652A BR PI0923652 A BRPI0923652 A BR PI0923652A BR PI0923652 A2 BRPI0923652 A2 BR PI0923652A2
Authority
BR
Brazil
Prior art keywords
treatment
cancer diagnosis
lgr7 antibody
lgr7
antibody
Prior art date
Application number
BRPI0923652A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Shinichi Funahashi
Yuriko Uehara
Original Assignee
Forerunner Pharma Res Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Res Co Ltd, Univ Tokyo filed Critical Forerunner Pharma Res Co Ltd
Publication of BRPI0923652A2 publication Critical patent/BRPI0923652A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0923652A 2008-12-26 2009-12-25 diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 BRPI0923652A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008333149 2008-12-26
PCT/JP2009/071524 WO2010074192A1 (ja) 2008-12-26 2009-12-25 抗lgr7抗体を用いる癌の診断および治療

Publications (1)

Publication Number Publication Date
BRPI0923652A2 true BRPI0923652A2 (pt) 2016-10-18

Family

ID=42287797

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923652A BRPI0923652A2 (pt) 2008-12-26 2009-12-25 diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Country Status (12)

Country Link
US (2) US20120014870A1 (pt)
EP (1) EP2377891B1 (pt)
JP (1) JP5801557B2 (pt)
KR (1) KR20110099762A (pt)
CN (1) CN102395603A (pt)
AU (1) AU2009331178A1 (pt)
BR (1) BRPI0923652A2 (pt)
CA (1) CA2748990A1 (pt)
MX (1) MX2011006908A (pt)
RU (1) RU2011131071A (pt)
SG (1) SG172427A1 (pt)
WO (1) WO2010074192A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677367T3 (es) * 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CN102636655B (zh) * 2012-05-10 2014-07-23 苏州大学附属第一医院 一种荧光原位微量淋巴毒检测方法和试剂盒
US10711153B2 (en) * 2013-09-27 2020-07-14 Stora Enso Oyj Composition comprising lignin and epoxy compound for coating and method for the manufacturing thereof and use thereof
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HUE068868T2 (hu) * 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
CN110337448B (zh) * 2016-12-23 2023-08-08 瑞美德生物医药科技有限公司 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
CN113692284A (zh) * 2018-11-20 2021-11-23 海德堡大学 用于治疗和预防心力衰竭的松弛素受体1
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2425712C (en) * 2000-10-04 2017-06-06 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002324727A1 (en) 2001-08-17 2003-03-03 The Board Of Trustees Of The Leland Stanford Junior University Mammalian relaxin receptors
AU2003224112A1 (en) 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7)
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
US20090215711A1 (en) 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
EP2123754B1 (en) 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR

Also Published As

Publication number Publication date
RU2011131071A (ru) 2013-02-10
US20200157231A1 (en) 2020-05-21
AU2009331178A1 (en) 2011-08-11
SG172427A1 (en) 2011-07-28
MX2011006908A (es) 2011-10-06
EP2377891A1 (en) 2011-10-19
JPWO2010074192A1 (ja) 2012-06-21
CN102395603A (zh) 2012-03-28
EP2377891B1 (en) 2018-11-21
CA2748990A1 (en) 2010-07-01
EP2377891A4 (en) 2012-08-29
JP5801557B2 (ja) 2015-10-28
WO2010074192A1 (ja) 2010-07-01
KR20110099762A (ko) 2011-09-08
US20120014870A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
BRPI0719202A2 (pt) Diagnóstico e tratamento de câncer usando anticorpo antiereg
PT2247620T (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
PT2474557E (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BRPI0822064A2 (pt) Dispositivos de imageamento fotoacústico e métodos de imageamento
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112012005594A2 (pt) tratamento de câncer
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0910854A2 (pt) métodos de tratamento
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PL2282675T3 (pl) System do zabiegu kosmetycznego i obrazowania
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
BRPI0919748A2 (pt) dipositivo de tratamento
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NO 020130046756/RJ DE 28.05.2013 SEJA CONHECIDA, DEVERA SER APRESENTADO DOCUMENTO DE PROCURACAO, OUTORGADO POR TODOS OS DEPOSITANTES, NO ORIGINAL OU COPIA AUTENTICADA, DANDO AO PROCURADOR PODERES PARA DESISTIR DO PEDIDO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130046756/RJ DE 28/05/2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO FOI CUMPRIDA A EXIGENCIA 6.7 PUBLICADA NA RPI 2224 DE 20/08/2013.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]